Latest From VeraLight Inc.
In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity.
- In Vitro Diagnostics
- Diagnostic Equipment & Supplies
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- VeraLight Inc.
- Senior Management
David Van Avermaete, CEO
Mirasol Panlilio, VP, Mktg. & Sales
- Contact Info
Phone: (505) 272-7023
800 Bradbury SE, Ste. 217
Albuquerque, NM 87106
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.